20,256 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. acquired a new position in IDEXX Laboratories, purchasing 20,256 shares valued at approximately $8.5 million.
• Several institutional investors, including Vanguard and Principal Financial Group, increased their stakes in IDEXX, with the company now having 87.84% of its stock owned by such entities.
• IDEXX Laboratories reported Q2 earnings of $3.63 EPS, exceeding estimates and reflecting a 10.6% year-over-year revenue growth.

Capital Fund Management S.A. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 20,256 shares of the company's stock, valued at approximately $8,507,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in IDEXX Laboratories by 1.5% in the first quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company's stock valued at $4,139,001,000 after buying an additional 146,427 shares during the last quarter. Bamco Inc. NY increased its stake in shares of IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after buying an additional 82,264 shares during the period. Invesco Ltd. increased its stake in shares of IDEXX Laboratories by 0.5% during the first quarter. Invesco Ltd. now owns 1,166,406 shares of the company's stock worth $489,832,000 after buying an additional 5,418 shares during the period. Principal Financial Group Inc. increased its stake in shares of IDEXX Laboratories by 58.3% during the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after buying an additional 414,802 shares during the period. Finally, GAMMA Investing LLC increased its stake in IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after purchasing an additional 916,898 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Activity

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the transaction, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Nimrata Hunt sold 7,143 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the sale, the executive vice president owned 18,007 shares of the company's stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,870 shares of company stock worth $32,877,757 over the last 90 days. Insiders own 0.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IDXX. Leerink Partners raised their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target for the company. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Morgan Stanley raised their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a report on Friday, August 15th. Finally, BTIG Research raised their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $633.05 on Friday. The stock's 50 day moving average price is $567.48 and its 200 day moving average price is $492.73. The firm has a market capitalization of $50.64 billion, a PE ratio of 52.71, a price-to-earnings-growth ratio of 4.14 and a beta of 1.49. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories's revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.